In November 2024, Montmorillonite Powder (specification: each sachet contains 3g of montmorillonite), independently researched, developed and manufactured by Zhejiang Asen Pharmaceutical Co., Ltd., was approved by the National Medical Products Administration (NMPA) (Drug Approval Number: Guo Yao Zhun Zi.H20249266).
Montmorillonite Powder is an over-the-counter (OTC) drug commonly used in clinical practice for the treatment of acute and chronic diarrhea in adults and children. After more than three years of R&D, the company’s self-developed preparation achieved quality consistency with the reference listed drug and received recognition from the NMPA, successfully obtaining the Drug Registration Certificate.
As the first generic drug product independently researched, developed and manufactured by the company, the approval of Montmorillonite Powder will enrich the product pipeline and enhance market competitiveness. It not only demonstrates the company’s strength and experience in generic drug R&D and manufacturing but also reflects its persistent pursuit of drug quality control.
In the future, the company will continue to adhere to its corporate mission of "Creating Wealth, Fulfiling Employees, and Benefiting Society ", further expand researched, developed and manufactured in the generic drug field, leverage its accumulated technical expertise and R&D experience, and launch more safe and effective drugs to contribute to the cause of public health.